Skip to main content
LEGN
NASDAQ Life Sciences

Legend Biotech Swings to Q3 Profit: $51.7M Net Income, $359.5M Revenue

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$24.43
Mkt Cap
$4.707B
52W Low
$16.24
52W High
$37.5
52W Position info
50% above low
Off High info
35% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LEGN sits 50% above its 52-week low of $16.24.

Summary

Legend Biotech reported Q3 2026 net income of $51.7M ($0.13 per share) on revenue of $359.5M, versus a $39.6M loss a year ago, as CARVYKTI net trade sales grew 36% to about $710M. Cash and time deposits stood at roughly $853M at September 30.


Key Events · Earnings and Guidance · LEGN

  • Q3 Swing to Profit

    Net income of $51.7M ($0.13 per diluted share) versus a $39.6M loss in Q3 2025; operating income of $46.8M versus a $43.3M operating loss.

  • CARVYKTI Sales Up 36%

    Net trade sales of approximately $710M drove collaboration revenue of $353.2M, up $91.4M year over year; total revenue was $359.5M versus $272.4M.

  • Cost Base Shrinks

    R&D fell $17.9M to $95.3M as cilta-cel trial dosing concluded, and administrative expense fell $19.9M to $14.8M on a share-based compensation reversal from forfeited awards.

  • Liquidity and Janssen Advance

    Cash and cash equivalents plus time deposits of approximately $853M at September 30, 2026; the Janssen funding advance was cut to $44.1M from $319.1M at December 31, 2025.


Analysis · LEGN · Life Sciences

Profitability arrived on a quarterly basis: operating income of $46.8M versus a $43.3M operating loss a year ago, and net income of $51.7M versus a $39.6M loss. CARVYKTI is the driver, with net trade sales up 36% to roughly $710M pushing collaboration revenue $91.4M higher to $353.2M. Costs moved the right way too — R&D fell $17.9M as the cilta-cel trial dosing phases wound down, and administrative expense dropped $19.9M largely on a share-based compensation reversal from forfeited awards. On the balance sheet, about $853M in cash and time deposits provides comfort, and the Janssen funding advance is down to $44.1M from $319.1M at year-end after non-cash offsets and repayments. The offsetting item is tax: nine-month expense jumped to $21.2M from $3.0M as taxable income rose across the U.S., Belgium and China, and the company is still negotiating an advance pricing agreement with the Chinese Tax Authority, so the final liability could differ materially from what is accrued.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LEGN was trading at $24.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LEGN - Latest Insights

LEGN
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $23.76
Real-time Price: $23.45 info
Change: -$0.310 (-1%) info
Market Cap: $4.707B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $19.11
Real-time Price: $23.45 info
Change: +$4.34 (+23%) info
Market Cap: $4.707B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.10
Real-time Price: $23.45 info
Change: +$4.35 (+23%) info
Market Cap: $4.707B info
LEGN
Oct 13, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.10
Real-time Price: $23.45 info
Change: +$5.35 (+30%) info
Market Cap: $4.707B info
LEGN
Sep 25, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $19.12
Real-time Price: $23.45 info
Change: +$4.33 (+23%) info
Market Cap: $4.707B info